Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587813 | 0.81 | MEN1 (0.33) | MEN1KMT2AHTTGAAALDH1A1 | |
| SCHEMBL1711066 | 0.80 | GPR119 (0.37) | MEN1KMT2AHTTGAAALDH1A1 | |
| SCHEMBL2694440 | 0.79 | BRS3 (0.34) | MEN1KMT2A | |
| SCHEMBL11912165 | 0.79 | BRS3 (0.34) | MEN1KMT2A | |
| SCHEMBL13458326 | 0.75 | MEN1 (0.40) | MEN1KMT2AHTTGAAALDH1A1 | |
| SCHEMBL13458086 | 0.72 | MEN1 (0.41) | MEN1KMT2AHTTGAAALDH1A1 | |
| SCHEMBL16587826 | 0.72 | MEN1 (0.32) | MEN1KMT2AHTTGAATXNRD1 | |
| SCHEMBL17221080 | 0.72 | KMT2A (0.39) | MEN1KMT2AHTTGAAALDH1A1 | |
| SCHEMBL17221079 | 0.72 | KMT2A (0.39) | MEN1KMT2AHTTGAAALDH1A1 | |
| SCHEMBL16587820 | 0.71 | HTT (0.37) | MEN1KMT2AHTTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168794-B2 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | MEN1 3664/4885KMT2A 1446/4885HTT 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.